Lowering low-density lipoprotein cholesterol: from mechanisms to therapies

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• High plasma levels of low-density lipoprotein cholesterol (LDL-C) are a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).
• LDL-C lowering is a cornerstone strategy in ASCVD prevention and treatment.
• Current therapies include statins, ezetimibe, and PCSK9 inhibitors, with novel agents emerging for specific patient populations.

Purpose of the Study:

• To review recent advances in LDL-C-lowering drugs.
• To elucidate the mechanisms of action for various LDL-C-lowering therapies.
• To discuss emerging strategies for managing hypercholesterolemia and reducing cardiovascular risk.

Main Methods:

• Review of current literature on LDL-C-lowering pharmacotherapies.
• Analysis of mechanisms of action for established and novel lipid-lowering agents.
• Discussion of therapeutic strategies for diverse patient profiles, including those with genetic lipid disorders.

Main Results:

• Established therapies like statins, ezetimibe, and PCSK9 inhibitors effectively reduce LDL-C.
• Emerging drugs, including ATP-citrate lyase inhibitors, offer new treatment avenues.
• Investigational therapies targeting cholesteryl ester transfer protein and novel pathways show promise for further LDL-C reduction.

Conclusions:

• A range of effective LDL-C-lowering therapies are available, with ongoing development of novel agents.
• Understanding drug mechanisms is key to optimizing lipid management and cardiovascular risk reduction.
• Personalized therapeutic approaches are essential, especially for patients with statin intolerance or genetic conditions affecting LDL metabolism.